These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15083182)

  • 21. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
    Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
    Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
    Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
    Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.
    Maxwell AJ; Clements K; Hilton B; Dodwell DJ; Evans A; Kearins O; Pinder SE; Thomas J; Wallis MG; Thompson AM;
    Eur J Surg Oncol; 2018 Apr; 44(4):429-435. PubMed ID: 29398324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
    Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
    Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
    Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Smeets A; Slembrouck L; Neven P; Nevelsteen I; Weltens C; Van Limbergen E; Christiaens MR; Van Ongeval C; Wildiers H; Libbrecht L; Floris G
    Eur J Surg Oncol; 2019 Apr; 45(4):550-559. PubMed ID: 30454971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
    Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
    Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnostic challenge of low-grade ductal carcinoma in situ.
    Onega T; Weaver DL; Frederick PD; Allison KH; Tosteson ANA; Carney PA; Geller BM; Longton GM; Nelson HD; Oster NV; Pepe MS; Elmore JG
    Eur J Cancer; 2017 Jul; 80():39-47. PubMed ID: 28535496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 36. Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis.
    Wärnberg F; Casalini P; Nordgren H; Bergkvist L; Holmberg L; Ménard S
    Breast Cancer Res Treat; 2002 Jun; 73(3):215-21. PubMed ID: 12160327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma.
    Logullo AF; Godoy AB; Mourão-Neto M; Simpson AJ; Nishimoto IN; Brentani MM
    Braz J Med Biol Res; 2002 Aug; 35(8):913-9. PubMed ID: 12185383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
    Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
    Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast.
    Catteau X; Simon P; Vanhaeverbeek M; Noël JC
    PLoS One; 2013; 8(3):e57773. PubMed ID: 23469238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.